EyePoint Pharmaceuticals (EYPT) News Today → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free EYPT Stock Alerts $12.09 -0.58 (-4.58%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEyePoint Pharmaceuticals (NASDAQ:EYPT) Rating Lowered to Sell at StockNews.comamericanbankingnews.com - May 11 at 2:24 AMEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challengesfinance.yahoo.com - May 10 at 4:03 PMChardan Capital Comments on EyePoint Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:EYPT)marketbeat.com - May 10 at 10:21 AMCormorant Asset Management, Lp Buys 850,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stockamericanbankingnews.com - May 10 at 4:56 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up on Insider Buying Activityamericanbankingnews.com - May 10 at 2:36 AMInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Acquires $10,081,000.00 in Stockinsidertrades.com - May 9 at 8:25 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) to Post Q1 2024 Earnings of ($0.32) Per Share, Capital One Financial Forecastsamericanbankingnews.com - May 9 at 6:16 AMInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 850,000 Shares of Stockmarketbeat.com - May 8 at 6:54 PMEYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024investorplace.com - May 8 at 3:17 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38.00marketbeat.com - May 8 at 8:56 AMEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developmentsglobenewswire.com - May 8 at 7:00 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $30.00 by Analysts at Mizuhoamericanbankingnews.com - May 8 at 5:52 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $28.00 by Analysts at Chardan Capitalamericanbankingnews.com - May 8 at 5:52 AMMaintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study Setbackmarkets.businessinsider.com - May 7 at 6:10 PMEyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Programseekingalpha.com - May 7 at 6:10 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Given New $28.00 Price Target at Chardan Capitalmarketbeat.com - May 7 at 9:21 AMMaintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in wAMD Market Despite NPDR Study Setbackmarkets.businessinsider.com - May 7 at 4:23 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Rating of "Buy" by Analystsamericanbankingnews.com - May 7 at 1:30 AMEyePoint tumbles 30% premarket on failed Phase 2 studymsn.com - May 6 at 6:21 PMEyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)seekingalpha.com - May 6 at 6:21 PMWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?finance.yahoo.com - May 6 at 6:21 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $19.74marketbeat.com - May 6 at 5:55 PMmarketbeat.com - May 6 at 9:43 AMmarketbeat.com - May 6 at 7:00 AMEyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathyglobenewswire.com - May 6 at 7:00 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.9%marketbeat.com - April 29 at 5:31 PMThese Biotechs and IPOs Inspire Big Insider Buying247wallst.com - April 28 at 8:15 AMJennison Associates LLC Takes Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - April 25 at 7:27 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.6% marketbeat.com - April 24 at 6:15 PMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Position Lifted by Federated Hermes Inc.marketbeat.com - April 23 at 5:35 AMInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 581,765 Shares of Stockinsidertrades.com - April 23 at 4:18 AMCormorant Asset Management, Lp Buys 581,765 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stockmarketbeat.com - April 22 at 6:54 PMVeru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare moversmsn.com - April 20 at 9:47 AMBuy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMDmarkets.businessinsider.com - April 19 at 2:14 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading Volumemarketbeat.com - April 18 at 1:56 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 2%marketbeat.com - April 16 at 1:40 PMEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - April 16 at 7:00 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.7%marketbeat.com - April 15 at 2:50 PM35,000 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by DekaBank Deutsche Girozentralemarketbeat.com - April 15 at 5:16 AMStrong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapiesmarkets.businessinsider.com - April 13 at 8:53 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - April 12 at 2:17 AMEyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialistsglobenewswire.com - April 2 at 7:00 AMEyePoint Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:EYPT)marketbeat.com - March 21 at 11:26 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 4.7% Higher marketbeat.com - March 19 at 3:33 PMEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - March 18 at 7:00 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - March 18 at 2:23 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.2%marketbeat.com - March 13 at 2:16 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40marketbeat.com - March 11 at 11:01 AMScotia Capital Inc. Has $727,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - March 10 at 7:23 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%finance.yahoo.com - March 9 at 9:59 AM Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. EYPT Media Mentions By Week EYPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.380.58▲Average Medical News Sentiment EYPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼364▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CTKB News LAB News QTRX News PACB News NAUT News HBIO News BNGO News AXDX News OLK News TXG News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
